a public good project by the
Synthesis
Company
of California

© 2026

Víctor M. Villalobos | doi.page

0 works0 citations0 h-index

Víctor M. Villalobos

Johnson & Johnson (United States)(US)

Publications by Year

Research Areas

Sarcoma Diagnosis and Treatment, Plant tissue culture and regeneration, CAR-T cell therapy research, Peptidase Inhibition and Analysis, Cancer Immunotherapy and Biomarkers

Most-Cited Works

→ First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers(2019)575 cited
→ The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients(2020)460 cited
→ Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial(2020)438 cited
→ Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study(2020)389 cited
→ NCCN Guidelines Insights: Bone Cancer, Version 2.2017(2017)293 cited
→ Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma(2020)153 cited

→ Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis(2016)

130 cited

→ Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors(2017)130 cited

→ A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib(2013)119 cited

→ Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study(2021)116 cited